$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma – a randomized, controlled pilot study 원문보기

Bmc complementary and alternative medicine, v.12, 2012년, pp.172 - 172  

Kim, Kab-Choong (Division of Stomach surgery, Department of Surgery, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, Korea) ,  Yook, Jeong-Hwan (Division of Stomach surgery, Department of Surgery, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, Korea) ,  Eisenbraun, Jürgen (Abnoba GmbH, Pforzheim, Germany) ,  Kim, Byung-Sik (Division of Stomach surgery, Department of Surgery, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, Korea) ,  Huber, Roman (Center for Complementary Medicine, University Medical Center Freiburg, Freiburg, Germany)

Abstract AI-Helper 아이콘AI-Helper

BackgroundMistletoe (Viscum album L.) extracts are widely used in complementary cancer therapy. Aim of this study was to evaluate safety and efficacy of a standardized mistletoe extract (abnobaVISCUM® Quercus, aVQ) in patients with gastric cancer.Patients and Methods32 operated gastric cancer pa...

주제어

참고문헌 (35)

  1. Dicken BJ Bigam DL Cass C Mackey JR Joy AA Hamilton SM Gastric adenocarcinoma: review and considerations for future directions Ann Surg 2005 241 27 39 15621988 

  2. Shin HR Jung KW Won YJ Park JG 2002 Annual Report of the Korea Central Cancer Registry: Based on Registered Data from 139 Hospitals Cancer Res Treat 2004 36 103 114 10.4143/crt.2004.36.2.103 20396549 

  3. Green D Ponce de Leon S Leon-Rodriguez E Sosa-Sanchez R Adenocarcinoma of the stomach: univariate and multivariate analysis of factors associated with survival Am J Clin Oncol 2002 25 84 89 10.1097/00000421-200202000-00018 11823704 

  4. Davis PA Sano T The difference in gastric cancer between Japan, USA and Europe: what are the facts? what are the suggestions? Crit Rev Oncol Hematol 2001 40 77 94 10.1016/S1040-8428(00)00131-1 11578917 

  5. Bussing A Bischof M Hatzmann W Bartsch F Soto-Vera D Fronk EM Gmeindl M Stein GM Prevention of surgery-induced suppression of granulocyte function by intravenous application of a fermented extract from Viscum album L. in breast cancer patients Anticancer Res 2005 25 4753 4757 16334172 

  6. Ogawa K Hirai M Katsube T Murayama M Hamaguchi K Shimakawa T Naritake Y Hosokawa T Kajiwara T Suppression of cellular immunity by surgical stress Surgery 2000 127 329 336 10.1067/msy.2000.103498 10715990 

  7. Physicians information about 5-FU http://www.fachinfo.de/data/fi/pdf/00/18/001835.pdf 

  8. Chau I Norman AR Cunningham D Iveson T Hill M Hickish T Lofts F Jodrell D Webb A Tait D Ross PJ Shellito P Oates JR Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer Eur J Cancer 2005 41 11 1551 1559 10.1016/j.ejca.2005.01.027 16026692 

  9. Paoletti X Oba K Burzykowski T Michiels S Ohashi Y Pignon JP Rougier P Sakamoto J Sargent D Sasako M Van Cutsem E Buyse M GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis JAMA 2010 303 17 1729 1737 20442389 

  10. Sano T Aiko T New Japanese classifications and treatment guidelines for gastric cancer: revision concepts and major revised points Gastric Cancer 2011 14 2 97 100 10.1007/s10120-011-0040-6 21573921 

  11. Wu AW Xu GW Wang HY Ji JF Tang JL Neoadjuvant chemotherapy versus none for resectable gastric cancer Cochrane Database Syst Rev 2007 18 2 CD005047 Apr 

  12. Horneber MA Bueschel G Huber R Linde K Rostock M Mistletoe therapy in oncology. Cochrane Database Syst Rev Cochrane Database 2008 16 2 CD003297 Apr 

  13. Büssing A Rosenberger A Stumpf A Schietzel M Development of lymphocyte subsets in tumor patients after subcutaneous administration of mistletoe extracts Forsch Komplementarmed 1999 6 4 196 204 10.1159/000021253 10529579 

  14. Schink M Tröger W Goyert A Scheuerecker H Selbmann HK Glaser F Correlation of NK cell activity against autologous tumour cells and K562 cells with the clinical outcome during therapy with mistletoe extracts Forsch Komplementarmed 2006 13 3 147 155 10.1159/000092624 

  15. Huber R Lüdtke H Wieber J Beckmann C Safety and effects of two mistletoe preparations on production of Interleukin-6 and other immune parameters - a placebo controlled clinical trial in healthy subjects BMC Complement Altern Med 2011 11 116 10.1186/1472-6882-11-116 22114899 

  16. Takeuchi H Maehara Y Tokunaga E Koga T Kakeji Y Sugimachi K Prognostic significance of natural killer cell activity in patients with gastric carcinoma: a multivariate analysis Am J Gastroenterol 2001 96 2 574 578 10.1111/j.1572-0241.2001.03535.x 11232710 

  17. Hong WS Min YI Son YS Hong SI Peripheral blood lymphocyte subsets in patients with stomach cancer J Korean Med Sci 1995 10 3 164 168 8527041 

  18. Loose D Van de Wiele C The immune system and cancer Cancer Biother Radiopharm 2009 24 3 369 376 10.1089/cbr.2008.0593 19538060 

  19. Bocci V Mistletoe (viscum album) lectins as cytokine inducers and immunoadjuvant in tumor therapy A review. J Biol Regul Homeost Agents 1993 7 1 6 

  20. Mengs U Gothel D Leng-Peschlow E Mistletoe extracts standardized to mistletoe lectins in oncology: review on current status of preclinical research Anticancer Res 2002 22 1399 1407 12168816 

  21. Stauder H Kreuser ED Mistletoe extracts standardised in terms of mistletoe lectins (ML I) in oncology: current state of clinical research Onkologie 2002 25 374 380 10.1159/000066058 12232491 

  22. Rostock M Huber R Greiner T Fritz P Scheer R Schueler J Fiebig HH Anticancer activity of a lectin-rich mistletoe extract injected intratumorally into human pancreatic cancer xenografts Anticancer Res 2005 25 1969 1975 16158932 

  23. Bantel H Engels IH Voelter W Schulze-Osthoff K Wesselborg S Mistletoe lectin activates caspase-8/FLICE independently of death receptor signaling and enhances anticancer drug-induced apoptosis Cancer Res 1999 59 2083 2090 10232592 

  24. Scheer R Errenst M Scheffler A Wirtsbaumbedingte Unterschiede von Mistelpräparaten Dtsch. Zschr. Onkol 1995 27 6 143 149 

  25. Kienle GS Kiene H Review article: Influence of Viscum album L (European mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies Integr Cancer Ther 2010 9 2 142 157 10.1177/1534735410369673 20483874 

  26. Rostock M Huber R Randomized and double-blind studies--demands and reality as demonstrated by two examples of mistletoe research Forsch Komplementarmed 2004 Suppl 1 18 22 

  27. Huber R Eisenbraun J Miletzki B Adler M Scheer R Klein R Gleiter CH Pharmacokinetics of natural mistletoe lectins after subcutaneous injection Eur J Clin Pharmacol 2010 66 9 889 897 10.1007/s00228-010-0830-5 20467733 

  28. Barsevick A Frost M Zwinderman A Hall P Halyard M GENEQOL Consortium I'm so tired: biological and genetic mechanisms of cancer-related fatigue Qual Life Res 2010 19 10 1419 1427 10.1007/s11136-010-9757-7 20953908 

  29. Huber R Rostock M Goedl R Ludtke R Urech K Buck S Klein R Mistletoe treatment induces GM-CSF- and IL-5 production by PBMC and increases blood granulocyte- and eosinophil counts: a placebo controlled randomized study in healthy subjects Eur J Med Res 2005 10 411 418 16287602 

  30. Romano F Uggeri F Crippa S Di Stefano G Scotti M Scaini A Immunodeficiency in different histotypes of radically operable gastrointestinal cancers J Exp Clin Cancer Res 2004 23 2 195 200 15354402 

  31. Romano F Cesana G Berselli M Gaia Piacentini M Caprotti R Bovo G Uggeri F Biological, histological, and clinical impact of preoperative IL-2 administration in radically operable gastric cancer patients J Surg Oncol 2004 88 4 240 247 10.1002/jso.20155 15565596 

  32. Romano F Cesana G Caprotti R Bovo G Uggeri F Piacentini MG Crippa S Uggeri F Preoperative IL-2 immunotherapy enhances tumor infiltrating lymphocytes (TILs) in gastric cancer patients Hepatogastroenterology 2006 53 70 634 638 16995478 

  33. Eisenbraun J Scheer R Kröz M Schad F Huber R Quality of life in breast cancer patients during chemotherapy and concurrent therapy with a mistletoe extract Phytomedicine 2011 18 2–3 151 157 20724129 

  34. Keefe DM Gibson RJ Mucosal injury from targeted anti-cancer therapy Support Care Cancer 2007 15 5 483 490 10.1007/s00520-006-0181-z 17103195 

  35. Walko CM Lindley C Capecitabine: a review Clin Ther 2005 27 1 23 44 10.1016/j.clinthera.2005.01.005 15763604 

관련 콘텐츠

오픈액세스(OA) 유형

GOLD

오픈액세스 학술지에 출판된 논문

저작권 관리 안내
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로